Poxel Announces Financial Calendar for 2022
04 Gennaio 2022 - 5:45PM
Business Wire
POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced its calendar for the publication of financial information
for 2022.
Event
Date*
2021 Fourth Quarter Financial Update
February 16, 2022
2021 Annual Results
March 23, 2022
2022 First Quarter Financial Update
May 17, 2022
2022 Second Quarter Financial Update
August 30, 2022
2022 First Half Results
September 21, 2022
2022 Third Quarter Financial Update
November 8, 2022
2022 Fourth Quarter Financial Update
February 15, 2023
* Subject to modification.
All corporate information on Poxel, including financial
statements, press releases and corporate presentations, is
available on the Investors page of the Company’s website.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing
innovative treatments for chronic serious diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare disorders. Poxel has clinical and earlier-stage programs from
its adenosine monophosphate-activated protein kinase (AMPK)
activator and deuterated TZD platforms targeting chronic and rare
metabolic diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator,
has successfully completed a Phase 2a proof-of-concept trial for
the treatment of NASH, which met its objectives. For the rare
inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that
targets mitochondrial dysfunction, has been approved and launched
for the treatment of type 2 diabetes in Japan. Poxel expects to
receive sales-based payments and royalties from Sumitomo Dainippon
Pharma. Poxel has a strategic partnership with Sumitomo Dainippon
Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine
other Southeast Asian countries. The Company intends to generate
further growth through strategic partnerships and pipeline
development. Listed on Euronext Paris, Poxel is headquartered in
Lyon, France, and has subsidiaries in Boston, MA, and Tokyo,
Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220104005717/en/
Poxel SA Aurélie Bozza Investor Relations &
Communication Senior Director aurelie.bozza@poxelpharma.com +33 6
99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
Investor relations / Media NewCap Emmanuel Huynh or
Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2023 a Apr 2024